-transparent.png){kind=logo}
Rapid carcinogenicity tests were done with transgenic (Tg) mice human prototype c-HRAS gene, namely BALB/cByJ x C57BL/6JF1-TgN(HRAS)2 or CB6F1-HRAS2 mice. The studies were conducted as the first step in the evaluation of the CB6F1-HRAS2 mouse as a model for the rapid carcinogenicity testing system. Results of short-term tests of various genotoxic carcinogens indicated that CB6F1-HRAS2 mice are more susceptible to these carcinogens than control non-Tg mice. According to the first-step evaluation studies, more rapid onset and a higher incidence of more malignant tumors can be expected with a higher probability after treatment with various genotoxic carcinogens in the CB6F1-HRAS2 mice than in control non-Tg mice. The CB6F1-HRAS2 mouse seems to be a promising candidate as an animal model for the development of a rapid carcinogenicity testing system.
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
December 1998,
Toxicology letters,
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
January 1992,
IARC scientific publications,
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
January 2002,
Toxicologic pathology,
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
January 2001,
Toxicologic pathology,
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
January 1998,
Toxicologic pathology,
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
June 2008,
Nucleosides, nucleotides & nucleic acids,
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
November 2002,
The Journal of veterinary medical science,
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
January 1994,
Acta veterinaria Hungarica,
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
January 1991,
Princess Takamatsu symposia,
S Yamamoto, and
Y Hayashi, and
K Mitsumori, and
T Nomura
March 2001,
Journal of experimental & clinical cancer research : CR,
